Background/Aims: Perinatal exposure to infections during critical developmental periods is a promising area of study in autism spectrum disorder (ASD). Epidemiological data has highlighted this relationship, pointing out significant correlations between perinatal exposure to pathogens and the occurrence of ASD. The aim of this review is to critically examine the present state of the art on intracellular pathogenic infection during pregnancy and postnatally, pointing out possible correlations with the development of ASD. Methods: We reviewed and collected studies concerning potential associations between intracellular pathogens like viral, bacterial, and parasite infection and the risk of ASD. Results: We included 14 publications, considering bacterial and/or viral infection that demonstrated the potential to trigger ASD. Nine case-control studies were included and 5 of them reported an association between infections and ASD. One of the 2 cohorts investigated demonstrated that maternal infection increased the risk of ASD in the offspring. Three cross-sectional studies demonstrated that ASD patients presented with chronic infections and active neuroinflammatory processes. Most of the reports suggest inflammatory response as a common factor, and interleukin 6 appears to be a key-player in this process. Conclusion: The immune responses generated by organisms that cause perinatal maternal infection, i.e., bacteria, viruses, or parasites, have been associated with the development of autism in offspring. Physiological changes transmitted from the mother during chronic or acute inflammation should be further investigated so that modulatory preventive measures can be developed.

Keywords:
Autism spectrum disorder, Pathogens, Infection, Inflammation
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5 (DSM-5) 2013. DOI: 10.1176/appi.books.9780890425596.744053.
2.
Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention (CDC): Prevalence of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63: 1–21.
3.
Chaste P, Leboyer M: Autism risk factors: genes, environment, and gene-environment interactions. Dialogues Clin Neurosci 2012; 14: 281–292.
4.
Constantino JN, Charman T: Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression. Lancet Neurol 2016; 15: 279–291.
5.
Torres AR, Sweeten TL, Johnson RC, Odell D, Westover JB, Bray-Ward P, et al: Common genetic variants found in HLA and KIR immune genes in autism spectrum disorder. Front Neurosci 2016; 10: 463.
6.
Bennabi M, Delorme R, Oliveira J, Fortier C, Lajnef M, Boukouaci W, et al: Dectin-1 polymorphism: a genetic disease specifier in autism spectrum disorders? PLoS One 2015; 10:e0137339.
7.
Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, et al: A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006; 103: 16834–16839.
8.
Patterson PH: Maternal infection and immune involvement in autism. Trends Mol Med 2011; 17: 389–394.
9.
Patterson PH: Maternal infection and autism. Brain Behav Immun 2012; 26: 393.
10.
Hsiao EY, Patterson PH: Placental regulation of maternal-fetal interactions and brain development. Dev Neurobiol 2012; 72: 1317–1326.
11.
Atladóttir HÓ, Thorsen P, Schendel DE, Østergaard L, Lemcke S, Parner ET: Association of hospitalization for infection in childhood with diagnosis of autism spectrum disorders. Arch Pediatr Adolesc Med 2010; 164: 470–477.
12.
Meyer U, Engler A, Weber L, Schedlowski M, Feldon J: Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 2008; 154: 701–709.
13.
Libbey JE, Sweeten TL, McMahon WM, Fujinami RS: Autistic disorder and viral infections. J Neurovirol 2005; 11: 1–10.
14.
Nicolson GL, Gan R, Nicolson NL, Haier J: Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and Human herpesvirus-6 coinfections in the blood of patients with autistic spectrum disorders. J Neurosci Res 2007; 85: 1143–1148.
15.
Chaidez V, Hansen RL, Hertz-Picciotto I: Gastrointestinal problems in children with autism, developmental delays or typical development. J Autism Dev Disord 2014; 44: 1117–1127.
16.
Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al: The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med 2014; 6: 263ra158.
17.
Goines P, Van de Water J: The immune system’s role in the biology of autism. Curr Opin Neurol 2010; 23: 111–117.
18.
Kugelberg E: Neuroimmunology: IL-17A mediates a path to autism 2016; 16: 205–205.
19.
Krakowiak P, Goines PE, Tancredi DJ, Ashwood P, Hansen RL, Hertz-Picciotto I, et al: Neonatal cytokine profiles associated with autism spectrum disorder. Biol Psychiatry 2017; 81: 442–451.
20.
Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57: 67–81.
21.
Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W: The impact of neuroimmune alterations in autism spectrum disorder. Front Psychiatry 2015; 6: 121.
22.
Careaga M, Water J, Ashwood P: Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 2010; 7: 283–292.
23.
Masi A, Breen EJ, Alvares GA, Glozier N, Hickie IB, Hunt A, et al: Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. Mol Autism 2017; 8: 63.
24.
Abdallah MW, Larsen N, Mortensen EL, Atladóttir HÓ, Nørgaard-Pedersen B, Bonefeld-Jørgensen EC, et al: Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank. J Neuroimmunol 2012; 252: 75–82.
25.
Rosen NJ, Yoshida CK, Croen LA: Infection in the first 2 years of life and autism spectrum disorders. Pediatrics 2007; 119:e61–e69.
26.
Atladóttir HÓ, Henriksen TB, Schendel DE, Parner ET: Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatrics 2012; 130:e1447–e1454.
27.
Singh VK, Lin SX, Yang VC: Serological association of measles virus and Human herpesvirus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol 1998; 89: 105–108.
28.
Burbelo PD, Swedo SE, Thurm A, Bayat A, Levin AE, Marques A, et al: Lack of serum antibodies against Borrelia burgdorferi in children with autism. Clin Vaccine Immunol 2013; 20: 1092–1093.
29.
Lintas C, Altieri L, Lombardi F, Sacco R, Persico AM: Association of autism with Polyomavirus infection in postmortem brains. J Neurovirol 2010; 16: 141–149.
30.
Gentile I, Zappulo E, Bonavolta R, Maresca R, Riccio MP, Buonomo AR, et al: Exposure to Varicella zoster virus is higher in children with autism spectrum disorder than in healthy controls. Results from a case-control study. In Vivo 2014; 28: 627–631.
31.
Gentile I, Zappulo E, Bonavolta R, Maresca R, Riccio MP, Buonomo AR, et al: Prevalence of herpes simplex virus 1 and 2 antibodies in patients with autism spectrum disorders. In Vivo 2014; 28: 667–671.
32.
Gentile I, Zappulo E, Coppola N, Bonavolta R, Portella G, Cernia DS, et al: Prevalence of HHV-6 and HHV-8 antibodies in patients with autism spectrum disorders. In Vivo 2013; 27: 843–849.
33.
Vojdani A, Campbell AW, Anyanwu E, Kashanian A, Bock K, Vojdani E: Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002; 129: 168–177.
34.
Carter CJ: Toxoplasmosis and polygenic disease susceptibility genes: extensive Toxoplasma gondii host/pathogen interactome enrichment in nine psychiatric or neurological disorders. J Pathog 2013; 2013: 1–29.
35.
Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, et al: Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 2015; 132: 161–179.
36.
Fond G, Boyer L, Gaman A, Laouamri H, Attiba D, Richard J-R, et al: Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study. J Psychiatr Res 2015; 63: 58–64.
37.
Sacco R, Militerni R, Frolli A, Bravaccio C, Gritti A, Elia M, et al: Clinical, morphological, and biochemical correlates of head circumference in autism. Biol Psychiatry 2007; 62: 1038–1047.
38.
Brown AS, Sourander A, Hinkka-Yli-Salomäki S, McKeague IW, Sundvall J, Surcel H-M: Elevated maternal C-reactive protein and autism in a national birth cohort. Mol Psychiatry 2014; 19: 259–264.
39.
Rossignol DA, Genuis SJ, Frye RE: Environmental toxicants and autism spectrum disorders: a systematic review. Transl Psychiatry 2014; 4:e360–e360.
40.
Goines P, Van de Water J: The immune system’s role in the biology of autism. Curr Opin Neurol 2010; 23: 111–117.
41.
Meyer U, Feldon J, Dammann O: Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011; 69: 26R–33R.
42.
Bransfield RC, Wulfman JS, Harvey WT, Usman AI: The association between tick-borne infections, Lyme borreliosis and autism spectrum disorders. Med Hypotheses 2008; 70: 967–974.
43.
Jyonouchi H, Geng L, Davidow AL: Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype? J Neuroinflammation 2014; 11: 187.
44.
Hagberg H, Gressens P, Mallard C: Inflammation during fetal and neonatal life: Implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012; 71: 444–457.
45.
Theoharides TC, Angelidou A, Alysandratos K-D, Zhang B, Asadi S, Francis K, et al: Mast cell activation and autism. Biochim Biophys Acta 2012; 1822: 34–41.
46.
Vojdani A, O’Bryan T, Green JAA, Mccandless J, Woeller KNN, Vojdani E, et al: Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci 2004; 7: 151–161.
47.
Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27: 10695–10702.
48.
Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, et al: HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 2012; 119: 5173–5181.
49.
Wei H, Alberts I, Li X: Brain IL-6 and autism. Neuroscience 2013; 252: 320–325.
50.
Onore C, Careaga M, Ashwood P: The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012; 26: 383–392.
51.
Baronio D, Castro K, Gonchoroski T, de Melo GM, Nunes GDF, Bambini-Junior V, et al: Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid. PLoS One 2015; 10:e0116363.
52.
Wright C, Shin JH, Rajpurohit A, Deep-Soboslay A, Collado-Torres L, Brandon NJ, et al: Altered expression of histamine signaling genes in autism spectrum disorder. Transl Psychiatry 2017; 7:e1126.
53.
Spijker S, Van Zanten JS, De Jong S, Penninx BWJH, van Dyck R, Zitman FG, et al: Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010; 68: 179–186.
54.
Abdallah MW, Hougaard DM, Nørgaard-Pedersen B, Grove J, Bonefeld-Jørgensen EC, Mortensen EL: Infections during pregnancy and after birth, and the risk of autism spectrum disorders: a register-based study utilizing a Danish historic birth cohort. Turk Psikiyatri Derg 2012; 23: 229–235.
55.
Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V: Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011; 68: 1104.
56.
Hamer M, Batty G, Marmot MG, Singh-Manoux A, Kivimäki M: Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav Immun 2011; 25: 168–173.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.